Kenneth Wen

2.0k total citations
52 papers, 1.3k citations indexed

About

Kenneth Wen is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kenneth Wen has authored 52 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 27 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Kenneth Wen's work include Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (15 papers). Kenneth Wen is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (15 papers). Kenneth Wen collaborates with scholars based in United States, China and Taiwan. Kenneth Wen's co-authors include Kenneth C. Anderson, Yu‐Tzu Tai, Nikhil C. Munshi, Chirag Acharya, Gang An, Xiaoyan Feng, Li Zhang, Lijie Xing, Paul G. Richardson and Lugui Qiu and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kenneth Wen

49 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth Wen United States 16 787 740 570 427 209 52 1.3k
Christina Krupka Germany 13 861 1.1× 502 0.7× 398 0.7× 594 1.4× 198 0.9× 25 1.3k
Berris van Kessel Netherlands 14 793 1.0× 963 1.3× 573 1.0× 438 1.0× 335 1.6× 33 1.5k
Inger S. Nijhof Netherlands 15 1.0k 1.3× 1.3k 1.7× 737 1.3× 555 1.3× 363 1.7× 37 1.9k
Denise Toscani Italy 18 557 0.7× 570 0.8× 571 1.0× 199 0.5× 51 0.2× 48 1.2k
Homer Adams United States 10 401 0.5× 401 0.5× 249 0.4× 237 0.6× 195 0.9× 25 713
Keegan Barry-Holson United States 8 403 0.5× 463 0.6× 521 0.9× 447 1.0× 72 0.3× 11 1.3k
Tinisha McDonald United States 12 543 0.7× 868 1.2× 753 1.3× 361 0.8× 29 0.1× 30 1.7k
Cathy S. Wang United States 12 451 0.6× 449 0.6× 328 0.6× 190 0.4× 240 1.1× 32 802
Siobhan Glavey United States 10 315 0.4× 448 0.6× 499 0.9× 206 0.5× 61 0.3× 19 853
Paola Storti Italy 17 546 0.7× 515 0.7× 460 0.8× 233 0.5× 29 0.1× 54 961

Countries citing papers authored by Kenneth Wen

Since Specialization
Citations

This map shows the geographic impact of Kenneth Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Wen more than expected).

Fields of papers citing papers by Kenneth Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Wen. The network helps show where Kenneth Wen may publish in the future.

Co-authorship network of co-authors of Kenneth Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Wen. A scholar is included among the top collaborators of Kenneth Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Wen. Kenneth Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dutta, Debasmita, Jiye Liu, Kenneth Wen, et al.. (2024). Lipid Nanoparticle-Mediated Combinational mRNA Vaccine for Multiple Myeloma: The Next Stage of Cancer Immunotherapy. Blood. 144(Supplement 1). 3278–3278. 1 indexed citations
2.
Kurata, Keiji, Mehmet Samur, Kenneth Wen, et al.. (2023). BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clinical Cancer Research. 29(9). 1807–1821. 19 indexed citations
3.
Dutta, Debasmita, Jiye Liu, Kenneth Wen, et al.. (2023). BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer Journal. 13(1). 184–184. 12 indexed citations
4.
5.
Liu, Jiye, Lijie Xing, Teru Hideshima, et al.. (2022). Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma. Blood. 140(Supplement 1). 360–361. 1 indexed citations
6.
Adamia, Sophia, Shruti Bhatt, Kenneth Wen, et al.. (2022). Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 36(4). 1088–1101. 10 indexed citations
7.
Xing, Lijie, Su Wang, Jiye Liu, et al.. (2021). BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clinical Cancer Research. 27(19). 5376–5388. 22 indexed citations
8.
Gullà, Annamaria, Eugenio Morelli, Mehmet Samur, et al.. (2021). Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer Discovery. 2(5). 468–483. 92 indexed citations
9.
Bianchi, Giada, Peter G. Czarnecki, Matthew Ho, et al.. (2021). ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discovery. 2(4). 338–353. 12 indexed citations
10.
Bae, Jooeun, Fabrizio Accardi, Teru Hideshima, et al.. (2021). Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 36(1). 138–154. 51 indexed citations
11.
Lin, Liang, Shih‐Feng Cho, Lijie Xing, et al.. (2020). Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 35(3). 752–763. 64 indexed citations
12.
Xing, Lijie, Liang Lin, Tengteng Yu, et al.. (2020). A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 34(8). 2150–2162. 50 indexed citations
13.
Tai, Yu‐Tzu, Liang Lin, Lijie Xing, et al.. (2018). APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 33(2). 426–438. 66 indexed citations
14.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2018). Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment. Blood. 132(Supplement 1). 592–592. 23 indexed citations
15.
Ho, Matthew, Jiye Liu, Alireza Kalbasi, et al.. (2017). Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function. Blood. 130. 4429–4429. 2 indexed citations
16.
Perini, Tommaso, Raphaël Szalat, Mariateresa Fulciniti, et al.. (2017). Bone Marrow Microenvironment Induces Genomic Instability and Enables Clonal Evolution in Multiple Myeloma. Blood. 130. 4408. 1 indexed citations
17.
Lin, Liang, Lijie Xing, Chirag Acharya, et al.. (2017). CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo. Blood. 130. 3067–3067. 6 indexed citations
18.
Szalat, Raphaël, Mehmet Samur, Mariateresa Fulciniti, et al.. (2017). Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 32(1). 111–119. 43 indexed citations
19.
An, Gang, Chirag Acharya, Xiaoyan Feng, et al.. (2016). Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication. Blood. 128(22). 3303–3303. 8 indexed citations
20.
Leng, Jing, Yuanyuan Zhang, Xin Yao, & Kenneth Wen. (2000). [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].. PubMed. 38(1). 40–3. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina Krupka Breakdown of academic impact, for papers by Berris van Kessel Breakdown of academic impact, for papers by Inger S. Nijhof Breakdown of academic impact, for papers by Denise Toscani Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Keegan Barry-Holson Breakdown of academic impact, for papers by Tinisha McDonald Breakdown of academic impact, for papers by Cathy S. Wang Breakdown of academic impact, for papers by Siobhan Glavey Breakdown of academic impact, for papers by Paola Storti
Rankless by CCL
2026